Until 2024, wearing a glucose sensor without diabetes meant paying a consumer platform to route you through its own telehealth network for a prescription you did not medically need. The subscription existed largely to carry that prescription.
The FDA's clearance of over-the-counter continuous glucose monitors removed that requirement. There are now three cleared sensors, two of them on sale today, and the economics of using one are no longer tied to a monthly plan. This page covers what the three are, what they give up compared to prescription sensors, and when a platform subscription is still the better purchase.
The Verdict
The three over-the-counter sensors
Listed alphabetically by product name. All three are sold directly by their manufacturers and through major pharmacy retailers.
| Sensor | Wear time | Price | Cleared for | Display range | Notes |
|---|---|---|---|---|---|
| Abbott Libre Rio | 14 days | Cleared June 2024; not yet on sale in the US, no price announced | Adults 18+ with type 2 diabetes not using insulin | Widest measurement range of the three at 40–400 mg/dL | Cleared for a narrower population than the other two |
| Abbott Lingo | 14 days | $54 for one sensor, $89 for two, $249 for six — $41.50–$54 per sensor | Adults 18+ not using insulin | App is built around a proprietary spike score alongside raw values | Lowest per-sensor price of the products actually on sale, on the six-sensor plan |
| Dexcom Stelo | 15 days | $99 one-time purchase | Adults 18+ not using insulin | Trend graph displays 70–250 mg/dL; readings outside that band appear only in Dexcom Clarity, not the main app | Dexcom states ~20% of sensors may not last the full 15 days |
Two manufacturers make all three. Dexcom produces Stelo; Abbott produces both Lingo and Libre Rio, positioned at different ends of its consumer line. Because the underlying sensing technology is shared with each company's prescription products, the choice between them is a choice about app design and per-day cost, not about measurement quality.
What over-the-counter sensors give up
Every OTC sensor is deliberately constrained, and the constraints follow from the clearance. Because these devices are cleared for adults not using insulin, none of them carries the safety features that insulin users depend on.
No low-glucose alarm. None of the three carries a low or urgent-low alert. For someone managing insulin, that alert is the entire point of the device — which is exactly why the clearance excludes insulin users. For someone tracking meal responses, its absence changes nothing.
Restricted display ranges — and not in the direction you would guess. Stelo's trend graph shows only 70–250 mg/dL; anything outside that band is available in Dexcom Clarity but not on the graph you actually look at. Libre Rio is the opposite case, carrying the widest measurement range of the three at 40–400 mg/dL, which Abbott presented as the point of the product. So an OTC sensor may truncate exactly the excursion you were trying to characterise — but which one does depends on the product, and the cheaper-looking option is the more constrained one here.
More smoothing. Stelo applies more aggressive filtering than its prescription counterpart. The result is a cleaner-looking curve with less noise, and also a slightly blunted peak — which matters if you are comparing the sharpness of two meals rather than their broad shape. Dexcom also states that around 20% of Stelo sensors may not run the full 15 days, so the effective per-day cost is a little higher than the sticker implies.
The economics, and why intermittent wear wins
Buying sensors outright changes the cost calculation, because you can now stop and restart without cancelling anything. The comparison below assumes a mid-priced OTC sensor against a typical consumer subscription platform.
| Usage pattern | OTC sensors, bought outright | Subscription platform | Who this fits |
|---|---|---|---|
| Two weeks, one-off | $41.50–$54 | $140–$250 (one month minimum on most plans) | Sampling your own responses once |
| Two weeks per quarter | $166–$216/yr | $560–$1,000+/yr if the subscription pauses; more if it does not | The pattern most people actually benefit from |
| Continuous, all year | $1,080–$1,400/yr | $1,700–$4,800/yr | Rarely justified without a clinical reason |
The middle row is the one worth planning around. Most of what a CGM teaches a non-diabetic arrives in the first 30–60 days: which of your regular meals spike you, how much a ten-minute walk after eating flattens the curve, what a short night or two drinks does to your fasting number. After that you are largely re-confirming known results. Two weeks each quarter re-checks those answers as your diet and training change, at roughly a quarter of the annual cost of continuous wear.
Insurance, HSA and FSA on an over-the-counter sensor
No insurance pathway exists for an OTC sensor bought by an adult without diabetes, and that is the direct trade-off for not needing a prescription. Insurers reimburse continuous glucose monitoring against a diagnosis code — typically type 1 diabetes, or type 2 on insulin — so a purchase made specifically to avoid the diagnostic step has nothing to bill against. Every OTC sensor is a cash purchase.
Health savings and flexible spending accounts are the useful exception, and the position here is better than it is for most longevity spending. A CGM sensor is a medical device, which makes it a qualified medical expense in a way that a clinic membership fee — billed as a retainer for access — generally is not. Paying with HSA or FSA money is effectively a 20–35% discount depending on your marginal rate. Some administrators ask for a letter of medical necessity for a non-diabetic user, so keep the receipt and check your plan's rules before assuming it clears.
One case inverts this page's whole recommendation. If you already carry a qualifying diagnosis, a prescription sensor routed through insurance is frequently cheaper than the OTC cash price — often substantially so after a deductible is met, and it comes with the alarms and full display range the OTC versions omit. Buying over the counter to skip a prescription you would actually qualify for is paying more for a more limited device.
OTC sensor vs subscription platform
Same sensor class, different product. The comparison below uses identical criteria for both.
| Criterion | OTC sensor | Subscription platform |
|---|---|---|
| Annual cost, quarterly use | $200–$440 | $560–$1,000+ (pausing a plan is not always possible) |
| Prescription required | No | Yes — issued through the platform's telehealth network |
| Interpretation layer | Manufacturer app only | Food logging, metabolic score, sometimes a dietitian consult |
| Commitment | Buy sensors as needed | Monthly or annual plan, minimum terms common |
| Where it falls short | No coaching; you interpret the curve yourself | You pay for the layer even after the learning plateaus |
| Verdict | Right if you can read your own data | Right if you want a human interpreting it |
Choose the OTC route if the sensor is what you were missing. Choose a platform if the interpretation is — Levels (levelshealth.com) and Nutrisense (nutrisense.io) differ mainly in how much human input the price includes, and the CGM hub compares them on one rubric. The decision that is almost never right is a multi-year subscription bought for the sensor alone, since that is now available without one.
Where a CGM belongs in the order of testing
A glucose sensor shows you the outcome of your metabolism in real time, but it cannot see the effort behind it. Someone with early insulin resistance often maintains normal glucose for years, because rising insulin output is holding the number down — a pattern a CGM reads as reassuring right up until it no longer is.
That is why fasting insulin and HOMA-IR belong before a sensor rather than after it. If you are choosing between one blood panel and one month of sensor wear, run the panel: it answers the question a CGM cannot. The sensor is at its most useful layered on top of a panel that already flagged something, or used to test which specific meals and habits move a number you already know is drifting.
Frequently Asked Questions
Can you buy a continuous glucose monitor over the counter?
Yes. In 2024 the FDA cleared the first continuous glucose monitors for over-the-counter sale in the US, and there are now three, listed alphabetically: Abbott Libre Rio, Abbott Lingo, and Dexcom Stelo. Two of the three are actually on sale — Lingo and Stelo, both direct from the manufacturer and through major pharmacy retailers. Libre Rio was cleared in June 2024 but has not launched in the US and Abbott has announced no price for it. All are sold without a prescription; the clearance is limited to adults who do not use insulin, because none carries the low-glucose alarm insulin users depend on.
What is the difference between an OTC CGM and a subscription platform?
The sensor hardware is the same class; the difference is what wraps it. A subscription platform bundles a telehealth prescription, a coaching or dietitian layer, food logging, and a proprietary metabolic score, and bills monthly. An over-the-counter sensor gives you the manufacturer's own app and nothing else. If you already know how to interpret a glucose curve, the platform layer is the part you are paying several hundred dollars a year for. If you want someone to tell you what the curve means, that layer is the product.
How much does an over-the-counter CGM cost?
Between roughly $41 and $54 per sensor for the two products on sale. Abbott Lingo is $54 for a single 14-day sensor, $89 for two, and $249 for six — so the per-sensor price falls from $54 to $41.50 as the plan lengthens. Dexcom Stelo is a $99 one-time purchase for 15-day sensors. Abbott Libre Rio has no announced price because it has not launched. Continuous year-round wear on Lingo therefore runs roughly $1,080–$1,400, which is why intermittent use — two weeks per quarter, at under $220 a year — is the pattern that captures most of the value.
Do over-the-counter CGMs have alarms?
None of the three carries a low or urgent-low glucose alarm, and that is the defining limitation — it is the safety feature insulin users depend on, and its absence is why the clearance is restricted to people not using insulin. Display range also differs sharply between them, in the opposite direction to what the marketing implies. Libre Rio has the widest measurement range of the three at 40–400 mg/dL. Stelo is the most constrained: its trend graph shows only 70–250 mg/dL, and readings outside that band appear in Dexcom Clarity rather than the main app. If you need a low alarm, you need a prescription sensor.
Is an over-the-counter CGM accurate?
The sensing technology is the same electrochemical filament used in the prescription versions, so raw sensor performance is comparable — mean absolute relative difference in the 8–10% range against laboratory reference values. What differs is the presentation layer. Stelo applies more smoothing than its prescription counterpart, which reduces noise but also blunts the sharpness of a real spike. All three share the interstitial lag of roughly 5–15 minutes behind blood glucose, which is a property of where the sensor sits rather than of the product tier.
Which over-the-counter CGM should I buy?
In practice the choice is between two, since Libre Rio has not launched. Abbott Lingo is the cheaper of the two on any multi-sensor plan, falling to $41.50 per sensor on the six-pack, and wraps the data in a proprietary spike score alongside raw values. Dexcom Stelo is a $99 one-time purchase with 15-day sensors and a plainer presentation, but its trend graph is capped at 70–250 mg/dL, so it will not render the extremes as numbers in the main app. If Libre Rio does launch it becomes the option to watch, because its 40–400 mg/dL range is the widest of the three. All use comparable sensing hardware, so this is a decision about display and price, not measurement quality.
Do I need a subscription for an over-the-counter CGM?
No — that is the main thing that changed. Both products on sale can be bought as individual sensors or short packs with no ongoing commitment, which makes intermittent use practical for the first time. Stelo is a straightforward one-time purchase, and Lingo sells single sensors and two-packs alongside its auto-renewing six-sensor plan. That plan is genuinely cheaper per sensor, but before signing up consider that most of the learning from a CGM arrives in the first 30–60 days, so a subscription that runs for years is usually buying diminishing returns.
Can non-diabetics use an over-the-counter CGM?
Yes, and that is precisely the market they were cleared for: adults 18 and over who do not use insulin. Whether it is useful is a separate question. A non-diabetic will see glucose rise after meals — typically to 120–140 mg/dL — and return to baseline within two to three hours, and that is normal physiology rather than a problem to fix. The genuinely useful outputs are your fasting number on waking, your 14-day average, and which of your own regular meals produce an unusually slow return to baseline.
Related
- CGM platforms compared — Levels, Nutrisense and Signos on one rubric
- CGM accuracy — MARD, interstitial lag, and false readings
- Levels review
- Nutrisense review
- Fasting insulin — the test that belongs before a sensor